The cables, chips, and switches connecting AI clusters are now the bottleneck the entire industry is racing to fix, and three mid-cap names are positioned at exactly that chokepoint before most retail investors realize the opportunity exists.
Here is how Astera Labs, Inc. (ALAB) and Allient (ALNT) have performed compared to their sector so far this year.
Astera Labs, Inc. (ALAB) concluded the recent trading session at $291.22, signifying a +2.35% move from its prior day's close.
Astera Labs benefits from record Aries revenues and strong Taurus growth as AI infrastructure demand expands, with Q3 revenues likely to be $540M to $560M.
Astera Labs stock has remained under pressure in the past few months, moving from the year-to-date high of $498 to the current $300. It has crawled back this month, and this recovery will likely continue in the coming months as demand for its products continues rising.
Astera Labs is gaining momentum from strong Scorpio, Aries and Taurus demand, with robust third-quarter growth expectations supporting its AI infrastructure story.
Astera Labs, Inc. (ALAB) reported earnings 30 days ago. What's next for the stock?
Astera's Q2 revenue grew 104% YoY, while Q3 guidance implies roughly 40% sequential growth as Scorpio accelerates. Scorpio should become Astera's largest product family one quarter early, with future content exceeding $1,000 per XPU. UALink, optics, Leo, and COSMOS could compound Astera's content opportunity across switching, memory connectivity, and workload orchestration.
Here is how Astera Labs, Inc. (ALAB) and Avnet (AVT) have performed compared to their sector so far this year.
Astera Labs rides on surging Scorpio X-Series demand, record revenues, and a rapid production increase as it battles Marvell and Credo in AI connectivity.
Astera Labs delivered record Q2 results, doubling revenue and nearly tripling net income on surging demand for AI data center infrastructure. ALAB benefits from hyperscaler-driven CapEx acceleration, positioning it to capture secular AI infrastructure growth and favorable product mix-driven margin expansion. Shares have corrected lately, presenting a buying opportunity at a discount to the historical valuation, with potential revaluation amid robust fundamentals.
ALAB is riding surging AI connectivity demand and Scorpio's ramp, while Credo targets over 80% fiscal 2027 growth as its optical portfolio expands.